Roche records failure in Phase III study of two lung cancer drugs
Roche’s Phase III study of using the combination of tiragolumab and tecentriq to treat a form of lung cancer did not achieve the desired success, the Swiss drugmaker said on Tuesday. The SKYSCRAPER-01 study ‘did not meet the primary endpoint of overall survival in the final analysis’ in patients with advanced or metastatic non-small cell lung cancer, it said.
ENTRADAS POPULARES
North Carolina city sues Duke Energy over climate crisis
diciembre 6, 2024
Earthquake of magnitude 5.7 strikes western Iran
diciembre 6, 2024
Soy traders push to soften ban on buying Amazon produce
diciembre 6, 2024
Tom Tykwer’s ‘The Light’ will open the 2025 Berlin Film Festival
diciembre 6, 2024
TRANSMISIÓN EN VIVO